WeTrials
Recruiting

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)

What is this study?

This clinical trial is testing a new way to treat recurrent brain cancer called glioma using a specialized treatment that delivers radiation directly to tumor cells. The goal is to find the safest and most effective dose of this new therapy to help patients whose cancer has returned.

Who can participate?

Adults aged 18 and older who have a confirmed diagnosis of aggressive, recurring brain cancer that has returned after standard treatments may be eligible. Participants must also be able to safely undergo MRI brain scans and have stable health conditions.

What will happen?

Participants will receive a specialized treatment using tiny fat bubbles carrying radiation directly into the brain area affected by the cancer. Doctors will carefully monitor safety and test different dose levels to see how well the treatment works.

Where and when?

This study is currently recruiting participants at multiple medical centers in New York and Texas. The team will guide you through the process and let you know what to expect at your specific location.

Key Points
  • 1Tests a direct radiation delivery treatment for recurring brain cancer
  • 2Open to adults 18 and older with confirmed recurrent glioma
  • 3Currently recruiting patients at study locations in New York and Texas

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Glioma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.